ID: MRFR/Pharma/2268-HCR | February 2021 | Region: Global | 80 pages
Market Synopsis of Global UTI treatment Market:
Urinary tract infection (UTI treatment) is the infection of the lower or upper urinary tract due to bacteria such as Escherichia coli, Staphylococcus saprophyticus etc. The symptoms of UTI treatment are pain with urination, frequent urination and urination feeling despite having an empty bladder. The market driving factors for UTI treatment are female anatomy, sexual intercourse, diabetes, obesity etc. Due to the complications of female anatomy UTI treatment affects females more than males with the World Health Organization (WHO) estimating that approximately 50 % of women suffer from UTI treatment at some point of time in their lives resulting in more than 1 million hospitalizations per year. It has further been stated that 1% of boys and 3-8% of girls are diagnosed with UTI treatment and the annual cost of UTI treatment infections treatment to be greater than $1 billion.
Key players of Global UTI treatment Market:
Key players profiled in the report are Bayer AG, Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd, AstraZeneca, Cipla Inc., Dr. Reddy’s Laboratories Ltd., Johnson & Johnson GlaxoSmithKline and others.
The Global UTI treatment Market is segmented on the basis of drug class which comprises of quinolones, aminoglycosides, β-lactam, azoles and others. On the basis of clinical indications this market is segmented into urethritis, cystitis, and pyelonephritis. On the basis of end users the market is segmented into hospitals and self-administered.
Figure 1 Global UTI Treatment Market by Drug Class, 2016 (% Market share)
U.S. accounts for the largest market share of the global UTI treatment market followed by Europe. However Europe has a greater hospitalization rate than the U.S. despite the U.S. having a large spending on healthcare. The regulatory changes in the U.S. such as implementation of Affordable Care Act and Hospital Readmissions Reduction Program coupled with Medicare initiative to penalize unnecessary patient readmissions is expected to take a toll on the U.S UTI treatment market. Asia pacific will be the fastest growing market and the growth will be led by China, and India as these nations have huge population and the low cost of UTI treatment drugs.
The report for Global UTI treatment Market by Market Research Future comprises of extensive primary research along with the detail analysis of qualitative as well as quantitative aspects by various industry experts, key opinion leaders to gain a deeper insight of the market and industry performance. The report gives a clear picture of current market scenario which includes past and estimated future market size with respect to value and volume, technological advancement, macro economical and governing factors in the market. The report provides detail information about and strategies used by top key players in the industry. The report also gives a broad study of the different market segments and regions.
Frequently Asked Questions (FAQ) :
The UTI treatment market is projected to grow at a 3.6% CAGR between 2018-2023.
The US is predicted to lead the UTI treatment market.
The UTI treatment market is predicted to touch USD 9.89 billion by 2023.
Growing health awareness and rising incidence of obesity are adding market growth.
Unmet clinical needs may limit market growth.
1.2 Scope of Study
1.3 Research Objective
1.4 Assumptions & Limitations
1.5 Market Structure:
2 Research Methodology
2.1 Research Process
2.2 Primary Research
2.3 Secondary Research
3 Market Dynamics
3.5 Macroeconomic Indicators
4 Market Factor Analysis
4.1 Porter’s Five Forces Model
4.1.1 Bargaining Power of Suppliers
4.1.2 Bargaining Power of Customer
4.1.3 Intensity of Competitor’s
4.1.4 Threat of New Entrants
5 Global UTI Drugs Market, by Drug Class
6 Global UTI Drugs Market, by Clinical Indications
7 Global UTI Drugs Market, by End User
8 Global UTI Drugs Market, by Country
8.4 Saudi Arabia
9 Company Landscape
9.1.1 Mergers Acquisitions
9.1.3 Release/New Product Launches
9.1.4 Other (Expansion, Updates, Partnership)
10 Company Profile
10.1 Bayer AG
10.1.1 Company Overview
10.1.2 Product/Business Segment Overview
10.1.4 Key Developments
10.1.5 SWOT Analysis
10.2 Novartis AG
10.2.2 Product/Business Segment Overview
10.2.4 Key Developments
10.2.5 SWOT Analysis
10.3 Pfizer Inc.
10.3.2 Product/Business Segment Overview
10.3.4 Key Developments
10.3.5 SWOT Analysis
10.4 F. Hoffmann-La Roche Ltd
10.4.2 Product/Business Segment Overview
10.4.4 Key Developments
10.4.5 SWOT Analysis
10.5.2 Product/Business Segment Overview
10.5.4 Key Developments
10.5.5 SWOT Analysis
10.6 Cipla Inc.
10.6.2 Product/Business Segment Overview
10.6.4 Key Developments
10.6.5 SWOT Analysis
10.7 Dr. Reddy’s Laboratories Ltd
10.7.2 Product/Business Segment Overview
10.7.4 Key Developments
10.7.5 SWOT Analysis
10.8 Johnson & Johnson
10.8.2 Product/Business Segment Overview
10.8.4 Key Developments
10.8.5 SWOT Analysis
11.1 Key Findings
11.1.1 From CEO’S Viewpoint
11.1.2 Unmet Needs of the Market
11.2 Key Companies to Watch
11.3 Prediction of UTI Treatment Industry